Pentoxifylline for heart failure: a systematic review.

摘要: Background. Recent trials have indicated a beneficial effect of pentoxifylline on measures of  inflammation and markers cardiac dysfunction in people with heart failure. However, it is uncertain whether should be used routinely the management Objective . To determine effectiveness Design Systematic review randomised controlled trials. Methods We searched MEDLINE (1 January 1966 - 20 November 2004), Cochrane Controlled Trials  Register (issue 4, reference lists related papers, for treatment Prospective, randomised, double-blind were sought inclusion study. The two reviewers independently assessed trial quality extracted data, which analysed using RevMan statistical software. following outcome evaluated: (i) New York Heart Association (NYHA) functional class; (ii) left ventricular ejection fraction (LVEF); (iii) frequency hospitalisation; (iv) death from all causes. Results. Four studies total 144 participants met criteria. Statistical pooling (or  meta-analysis) was not performed owing to significant clinical heterogeneity differences reporting outcomes included studies; instead, separately interest. four tested use versus placebo patients failure varying aetiology (idiopathic dilated cardiomyopathy, 3 ischaemic  1 study). In 2 idiopathic cardiomyopathy studies, classified as NYHA class II or III, while study population another in  IV. ischaemic classes I pen toxify !line associated improvement symptoms (i.e. Class) function LVEF) out 4 studies. seen grades severity cardiomyopathy. All showed trend towards reduction mortality, but this statistically significant. hospitalisation has been Interpretation.  Pentoxifylline may class, mortality failure, published are too small provide conclusive evidence. There need large, placebocontrolled involving diverse group regard cause